VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
Event:
ESC Congress 2025
Topic:
Lipid-Lowering Agents
Session:
Dyslipidaemias: current strategies and innovations
